Mometasone Eg (Mometasone Furoate)

Mometasone furoate, the active ingredient in Mometasone Eg, is a corticosteroid presented as an unspecified strength nasal spray for nasal use. It reduces inflammation associated with allergic rhinitis and nasal polyps in adults and children.

GNH USA supplies Mometasone Eg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mometasone furoate nasal spray acts on inflammatory pathways of the nasal mucosa to manage allergic and polyp‑related conditions. - Allergic rhinitis: relieves nasal congestion, itching and sneezing caused by seasonal or perennial allergens. - Seasonal allergic rhinitis: provides symptom control during pollen seasons. - Nasal polyps: reduces polyp size and improves nasal airflow in patients with chronic nasal polyposis.

Mometasone furoate nasal spray may cause local and systemic adverse reactions.

Common Side Effects: - Nasal irritation or burning sensation. - Epistaxis (nosebleeds). - Headache. - Sore throat. - Cough.

Serious or Rare Side Effects: - Adrenal suppression with prolonged high‑dose use. - Cataract formation or glaucoma. - Severe allergic reaction (anaphylaxis). - Opportunistic fungal infection of the nasal passages. - Nasal septum perforation.

Before initiating therapy, consider the following safety measures. - Assess patient history: evaluate recent nasal surgery, infection or trauma. - Review systemic corticosteroid use: avoid cumulative systemic exposure. - Monitor for signs of adrenal insufficiency during long‑term treatment. - Caution in patients with glaucoma or cataracts: regular ophthalmologic review may be needed. - Avoid use in children under the age recommended by local labeling without specialist advice. - Store at room temperature: keep in the original container, protect from moisture and direct heat.

Mometasone furoate nasal spray can interact with other medications that affect corticosteroid metabolism or increase systemic exposure.

Major Interactions (Avoid): - Concurrent systemic corticosteroids: heightened risk of systemic glucocorticoid effects. - Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir): may increase local drug levels.

Moderate Interactions (Monitor Closely): - Antifungal azoles (e.g., itraconazole): monitor for local irritation. - Nasal decongestants (e.g., oxymetazoline): assess for additive nasal mucosa effects. - Immunosuppressants (e.g., cyclosporine): watch for enhanced immunosuppression.